MA51066A - Inhibiteurs d'intégrine - Google Patents

Inhibiteurs d'intégrine

Info

Publication number
MA51066A
MA51066A MA051066A MA51066A MA51066A MA 51066 A MA51066 A MA 51066A MA 051066 A MA051066 A MA 051066A MA 51066 A MA51066 A MA 51066A MA 51066 A MA51066 A MA 51066A
Authority
MA
Morocco
Prior art keywords
integrin
inhibitors
Prior art date
Application number
MA051066A
Other languages
English (en)
Inventor
Andrea Bortolato
Matthew G Bursavich
Tyler Day
James E Dowling
Aleksey I Gerasyuto
Kristopher N Hahn
Bryce A Harrison
Eugene Hickey
Byungchan Kim
Kyle D Konze
fu-yang Lin
Blaise S Lippa
Qi Qiao
Bruce N Rogers
Brian Sosa
Mats A Svensson
Dawn M Troast
Cheng Zhong
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of MA51066A publication Critical patent/MA51066A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA051066A 2018-08-29 2019-08-29 Inhibiteurs d'intégrine MA51066A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10

Publications (1)

Publication Number Publication Date
MA51066A true MA51066A (fr) 2020-10-14

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051066A MA51066A (fr) 2018-08-29 2019-08-29 Inhibiteurs d'intégrine

Country Status (22)

Country Link
US (4) US20200071322A1 (fr)
EP (2) EP4086254A1 (fr)
JP (1) JP7540998B2 (fr)
KR (1) KR20210065935A (fr)
CN (1) CN112805001B (fr)
AU (1) AU2019327475A1 (fr)
BR (1) BR112021003859A2 (fr)
CA (1) CA3109534A1 (fr)
CL (1) CL2021000484A1 (fr)
CO (1) CO2021002706A2 (fr)
CR (1) CR20210109A (fr)
DO (1) DOP2021000035A (fr)
EC (1) ECSP21013620A (fr)
IL (1) IL280782A (fr)
MA (1) MA51066A (fr)
MX (1) MX2021002181A (fr)
PE (1) PE20211640A1 (fr)
PH (1) PH12021550404A1 (fr)
SG (1) SG11202101913PA (fr)
TW (1) TW202035400A (fr)
UY (1) UY38353A (fr)
WO (1) WO2020047239A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US11040955B2 (en) 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3760202A1 (fr) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TW201938158A (zh) 2018-03-07 2019-10-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115820A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composes pour l'inhibition de l'integrine .alpha.4.beta.7
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
JP2023541427A (ja) * 2020-09-11 2023-10-02 アローヘッド ファーマシューティカルズ インコーポレイテッド 骨格筋送達プラットフォーム及び使用方法
AU2021381516A1 (en) 2020-11-19 2023-06-22 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2024173570A1 (fr) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE αVβ8
WO2024173572A1 (fr) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE α Vβ8

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH07501063A (ja) 1991-11-14 1995-02-02 グラクソ、グループ、リミテッド フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
JPH07503459A (ja) 1992-01-21 1995-04-13 グラクソ、グループ、リミテッド 酢酸誘導体
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0906103A1 (fr) 1995-12-29 1999-04-07 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
WO1997026250A1 (fr) 1996-01-16 1997-07-24 Merck & Co., Inc. Antagonistes du recepteur integrine
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
NZ326874A (en) 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
EP0934305A4 (fr) 1996-08-29 2001-04-11 Merck & Co Inc Antagonistes de l'integrine
DE69720771T2 (de) 1996-10-30 2004-01-29 Merck & Co Inc Integrin antagonist
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
CA2286239A1 (fr) 1997-04-07 1998-10-15 Merck & Co., Inc. Procede de traitement du cancer
WO1998046220A1 (fr) 1997-04-14 1998-10-22 Merck & Co., Inc. Polytherapie pour la prevention et le traitement de l'osteoporose
IL136267A0 (en) 1997-11-26 2001-05-20 Du Pont Pharm Co 1,3,4-THIADIZOLES AND 1,3,4-OXADIAZOLES AS αVβ3 ANTAGONISTS
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU739811B2 (en) 1997-12-17 2001-10-18 Merck & Co., Inc. Integrin receptor antagonists
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
CA2315232A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU747784B2 (en) 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CZ20012212A3 (cs) 1998-12-19 2001-09-12 Merck Patent Gmbh Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje
EP1150965A4 (fr) 1999-02-03 2002-05-15 Merck & Co Inc Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CA2373937A1 (fr) 1999-06-02 2000-12-07 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
EP1252162B1 (fr) 2000-01-20 2012-07-25 Merck Sharp & Dohme Corp. Antagonistes du recepteur de l'integrine alpha v
EP1254116A4 (fr) 2000-01-24 2003-04-23 Merck & Co Inc Antagonistes du recepteur de l'integrine alpha v
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
EP1319002A1 (fr) 2000-09-14 2003-06-18 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
US20050004199A1 (en) 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
EP1387688A2 (fr) 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinones, antagonistes de recepteur d'integrine alpha v
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
PL219749B1 (pl) 2002-08-16 2015-07-31 Janssen Pharmaceutica Nv Pochodna piperydyny i jej zastosowanie oraz kompozycja farmaceutyczna ją zawierająca
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
CL2008001724A1 (es) 2007-06-13 2008-08-08 Bristol Myers Squibb Co Compuestos derivados de analogos dipeptidos, inhibidores del factor de coagulacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de un trastorno tromboembolico, infarto de miocardio, trombosis, ate
EP2221308B1 (fr) 2007-11-16 2013-07-10 Ube Industries, Ltd. Composé de benzazépinone
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
MX2015000794A (es) 2012-07-18 2015-10-12 Univ Saint Louis Derivados de aminoácido beta como antagonistas de integrina.
EP2784511A1 (fr) 2013-03-27 2014-10-01 Universität Zürich Intégrine alpha-v-beta6 pour le diagnostic/pronostic du carcinome colorectal
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (fr) 2014-01-06 2015-07-09 The General Hospital Corporation Antagonistes de l'intégrine
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (fr) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Inhibiteurs d'alpha (v) bêta 6, localisés dans les poumons
WO2016022851A1 (fr) 2014-08-06 2016-02-11 Children's Medical Center Corporation Polypeptides d'intégrine modifiés, dimères de polypeptides d'intégrine modifiés, et leurs utilisations
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
KR102647026B1 (ko) 2015-02-19 2024-03-12 사이플루어 라이프 사이언시즈, 인크 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
CN107428755B (zh) 2015-03-25 2020-03-03 富士胶片株式会社 含氮化合物或其盐的制造方法以及它们的制造中间体
CN108040467A (zh) 2015-04-30 2018-05-15 赛弗卢尔生命科学公司 四氢萘啶基丙酸衍生物及其用途
CN108779077A (zh) 2015-12-30 2018-11-09 圣路易斯大学 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
JP2019524702A (ja) 2016-07-05 2019-09-05 ザ ロックフェラー ユニバーシティー テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
ES2906109T3 (es) 2016-11-01 2022-04-13 Arrowhead Pharmaceuticals Inc Ligandos de la integrina alfa- v beta-6 y usos de los mismos
WO2018085578A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Inhibiteurs de l'intégrine en combinaison avec un agent qui interagit avec un récepteur de chimiokine
WO2018085552A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Antagonistes de l'intégrine
CA3042714A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Derives d'indazole en tant qu'antagonistes de l'integrine av
EA038164B1 (ru) 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
MA46746A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
BR112019009293A2 (pt) 2016-11-08 2019-07-30 Bristol-Myers Squibb Company pirrol amidas como inibidores de integrina alfa v
JP7264810B2 (ja) 2016-11-08 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物
EP3558303A4 (fr) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. Composés acides aminés et leurs procédés d'utilisation
BR112019012515A2 (pt) 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
US11040955B2 (en) * 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3760202A1 (fr) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TW201938158A (zh) 2018-03-07 2019-10-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020009889A1 (fr) 2018-07-03 2020-01-09 Saint Louis University Antagonistes de l'intégrine alphavbeta1
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
EP3843727A4 (fr) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
EP3843728A4 (fr) 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
TWI835840B (zh) 2018-08-29 2024-03-21 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020210404A1 (fr) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Formes posologiques et schémas de traitement pour des composés d'acides aminés

Also Published As

Publication number Publication date
WO2020047239A1 (fr) 2020-03-05
EP4086254A1 (fr) 2022-11-09
US20200354359A1 (en) 2020-11-12
CN112805001A (zh) 2021-05-14
PE20211640A1 (es) 2021-08-24
EP3617206A1 (fr) 2020-03-04
PH12021550404A1 (en) 2021-10-04
UY38353A (es) 2020-03-31
US11021480B2 (en) 2021-06-01
US11739087B2 (en) 2023-08-29
KR20210065935A (ko) 2021-06-04
IL280782A (en) 2021-04-29
DOP2021000035A (es) 2021-06-30
JP7540998B2 (ja) 2024-08-27
ECSP21013620A (es) 2021-05-31
CN112805001B (zh) 2024-07-23
MX2021002181A (es) 2021-07-15
TW202035400A (zh) 2020-10-01
AU2019327475A1 (en) 2021-03-11
US20200385384A1 (en) 2020-12-10
SG11202101913PA (en) 2021-03-30
CL2021000484A1 (es) 2021-09-03
CA3109534A1 (fr) 2020-03-05
BR112021003859A2 (pt) 2021-05-18
JP2021535141A (ja) 2021-12-16
CO2021002706A2 (es) 2021-05-20
US20220073511A1 (en) 2022-03-10
CR20210109A (es) 2021-06-24
US20200071322A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MA51066A (fr) Inhibiteurs d'intégrine
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA51616A (fr) Inhibiteurs d'adn-pk
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA47692A (fr) Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
DK3774817T3 (da) Bcl6-hæmmere
MA49006A (fr) Inhibiteurs d'ip6k
MA50906A (fr) Inhibiteurs d'immunoprotéasome
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
MA53009A (fr) Agents inhibiteurs d'ask1
IT201700087327A1 (it) Metodo di gestione termica dell'ats
UA42377S (uk) Комплект етикеток
UA42366S (uk) Комплект етикеток
UA42073S (uk) Комплект етикеток
UA41330S (uk) Комплект етикеток
UA40681S (uk) Комплект етикеток
UA41684S (uk) Комплект етикеток
UA40980S (uk) Комплект етикеток
UA40316S (uk) Комплект етикеток
UA40553S (uk) Комплект етикеток
UA40315S (uk) Комплект етикеток
UA41014S (uk) Комплект етикеток
UA40551S (uk) Комплект етикеток